



**COMMONWEALTH OF KENTUCKY  
 CABINET FOR HEALTH AND FAMILY SERVICES  
 DEPARTMENT FOR MEDICAID SERVICES  
 PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**  
 NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.  
 Tuesday, January 21, 2025  
 1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
<a href="#">Join the meeting now</a>  Meeting ID: 252 322 420 505 Passcode: Vo9JX9oX  <a href="#">Download Teams</a>   <a href="#">Join on the web</a>	+1-858-252-2734 (US Toll)  Phone Conference ID: 453 137 721#

## AGENDA

- I. **Call to Order and Welcome**
- II. **Executive Session (upon request)**
- III. **Old Business**
  - a. Approval of April 2024 Meeting Minutes
  - b. Approval of July 2024 Meeting Minutes
  - c. Approval of October 2024 Meeting Minutes
- IV. **New Business**
  - a. New Products to Market to be Reviewed as Single Products:
    - i. Cobenfy™ (*Antipsychotics, Second Generation (Atypical) and Injectable*)
    - ii. Livdelzi® (*Bile Salts*)
    - iii. Vyalev™ (*Parkinson’s Disease (Antiparkinson’s Agents)*)
    - iv. Ebglyss™ (*Immunomodulators – Atopic Dermatitis*)
    - v. Xdemvy™ (*Non-PDL*)
    - vi. Yorvipath™ (*Non-PDL*)
    - vii. Duvyzat™ (*Muscular Dystrophy Agents*)
    - viii. Nemluvio® (*Immunomodulators, Atopic Dermatitis*)
    - ix. Neffy® (*Epinephrine, Self-Injectable*)
    - x. Miplyffa™ (*Non-PDL*)
    - xi. Aqneursa™ (*Non-PDL*)



**V. Therapeutic Classes with Recommended Changes**

- a. Antibiotics: Gastrointestinal
- b. Antibiotics: Vaginal
- c. Antibiotics: Penicillins
- d. Antibiotics: Sulfonamides, Folate Antagonists
- e. Antifungals, Oral
- f. Hepatitis C Agents: Interferons and Ribavirins
- g. Chronic Obstructive Pulmonary Disease (COPD) Agents
- h. Epinephrine, Self-Injectable
- i. Glucocorticoids, Inhaled

**VI. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> <li>• Antibiotics, Cephalosporins 1<sup>st</sup> Generation</li> <li>• Antibiotics, Cephalosporins 2<sup>nd</sup> Generation</li> <li>• Antibiotics, Cephalosporins 3<sup>rd</sup> Generation</li> <li>• Antibiotics, Inhaled</li> <li>• Antibiotics, Macrolides</li> <li>• Antibiotics, Oxazolidinones</li> <li>• Antibiotics, Quinolones</li> <li>• Antibiotics, Tetracyclines</li> <li>• Antihistamines, Minimally Sedating</li> </ul>	<ul style="list-style-type: none"> <li>• Antiretrovirals, HIV/AIDS</li> <li>• Antivirals (Oral), Herpes</li> <li>• Antivirals (Oral), Influenza</li> <li>• Bronchodilators, Beta-Agonist</li> <li>• Hepatitis B Agents</li> <li>• Hepatitis C Agents: Direct-Acting Antivirals</li> <li>• Intranasal Rhinitis Agents</li> <li>• Leukotriene Modifiers</li> </ul>
--	--

**VII. Adjournment**

- a. Schedule of Upcoming Meetings
  - i. **April 15, 2025**
  - ii. **July 15, 2025**
  - iii. **October 14, 2025**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.